Session » Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

Date: Monday, November 6, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1355

14-3-3η: Useful for More Than the Diagnosis of Rheumatoid Arthritis?

9:00AM-11:00AM: Abstract Number: 1372

A Single Immunosignature Test Accurately Discriminates RA from Related Autoimmune and Inflammatory Disorders

9:00AM-11:00AM: Abstract Number: 1390

Agreement between the DAS28-ESR and the DAS28-CRP and Factors Related to the Discrepancies between Disease Activity Levels According to These 2 Scores in Patients with Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1397

American College of Rheumatology Response Rates Determined Using 28 Versus 68/66 Joint Count in Patients with Rheumatoid Arthritis Receiving Tofacitinib in Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 1357

Anti-Cyclic Citrullinated Peptide Antibody Positive Rheumatoid Arthritis Patients with Comorbid Post-Traumatic Stress Disorder Have Higher Serum Cytokine Expression

9:00AM-11:00AM: Abstract Number: 1362

Assessing the Quality, Reliability and Readability of Online Health Information Regarding Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1396

Can 3 0-10 Physician Visual Analog Scales (VAS) to Assess Levels of Inflammation, Damage and Distress Offer Comprehensive Quantitative Data That May be As Informative As Detailed, Formal Swollen and Tender Joint Counts?

9:00AM-11:00AM: Abstract Number: 1382

Characteristics of Patients with Rheumatoid Arthritis and Atlanto-Axial Pannus

9:00AM-11:00AM: Abstract Number: 1367

Circulating Microbial Small RNAs Are Altered in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1394

Comparison of Improvements in Disease Activity between Classes of Biologic Disease Modifying Anti-Rheumatic Drugs in Routine Clinical Practice: Findings from a Large Contemporaneous Real World Cohort

9:00AM-11:00AM: Abstract Number: 1342

Comprehensive Provider Judgment Outweighs Disease Activity Measures in the Decision to Not Escalate Therapy in Patients with Moderate to Severe Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1365

Correlation of the Multi-Biomarker Disease Activity Score with Composite Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1385

Decisional Conflict in Doctor – Patient Discussions about Disease Modifying Anti-Rheumatic Drugs

9:00AM-11:00AM: Abstract Number: 1371

Development of an Adjusted Multi-Biomarker Disease Activity (MBDA) Score for Rheumatoid Arthritis (RA) That Accounts for Age, Sex and Adiposity, with Subsequent Evaluation of Ability to Predict Risk for Radiographic Damage

9:00AM-11:00AM: Abstract Number: 1376

Diagnostic Performance of 7 Different Anti-Cyclic Citrullinated Peptide Antibody and 6 Rheumatoid Factor Assays in a Primary Diagnostic, Consecutive Rheumatological Population in a Secondary Care Hospital

9:00AM-11:00AM: Abstract Number: 1363

Disease Duration and Shared Epitope, but Not Smoking History, Are Associated with Peptidylarginine Deiminase 4-Antibody Development in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1392

Effect Size Comparison of Ultrasound Measures in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1379

Epithelial Neutrophil-Activating Peptide 78/C-X-C Motif Chemokine 5 in the Insulin Resistance of Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1366

Evaluation of Synovial Fluid 14-3-3η Protein As a Marker of Joint Damage in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1388

Fatigue Is Strongly Associated with the Patient Global Assessment and May Affect Disease Severity and Clinical Remission in Patients with Rheumatoid Arthritis: A Cross-Sectional Study from IORRA, a Large Observational Cohort of Japanese Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1354

Fatigue, Poor Health and Mood Disturbance Persist in Rheumatoid Arthritis and Psoriatic Arthritis Patients Despite Disease Remission: The OPAL Deeper Study

9:00AM-11:00AM: Abstract Number: 1374

Flares in Patients with Rheumatoid Arthritis Are Strongly Associated with Worse Clinical Outcomes but Are Difficult to Predict

9:00AM-11:00AM: Abstract Number: 1375

Foot Arthritis : Poor Prognosis Factor in RA

9:00AM-11:00AM: Abstract Number: 1343

Gingival Bleeding and Periodontitis in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study

9:00AM-11:00AM: Abstract Number: 1370

Higher Disease Activity in Current Smokers with Established RA: Is It Disease, Damage or Disability?

9:00AM-11:00AM: Abstract Number: 1361

How Often Do Rheumatologists Use Valid Prognostic Factors of Rheumatoid Arthritis? the Progresar Project

9:00AM-11:00AM: Abstract Number: 1344

Impact of Fibromyalgic RA on Composite Scores; Results from a Longitudinal Study of RA Patients Initiating Bdmard Therapy

9:00AM-11:00AM: Abstract Number: 1383

IMPACT of Smoking in the Expression of Periodontitis and Anticitrullinated Protein Antibodies in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1387

In-Depth Temperature of Small and Large Joints Assessed By Microwave Radiometry As an Additional Biomarker in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1364

Incidence of Rheumatoid Arthritis in a Cohort of First Degree Relatives from the Studies of the Etiology of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1369

Interferon Gamma Signature Genes and CXCL10 As New Biomarkers in Early Stage of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1356

Is ACPA-Positive RA Still a More Severe Disease Than ACPA-Negative RA? a Longitudinal Cohort Study in RA-Patients Treated from 2000 Onwards

9:00AM-11:00AM: Abstract Number: 1340

Is Depression in Patients with Rheumatoid Arthritis Associated with Disease Activity? Comparative Study between Germany and Brazil

9:00AM-11:00AM: Abstract Number: 1353

Is Joint Damage Due to Secondary Osteoarthritis (OA) Clinically As Important As Inflammation in Contemporary Management of Rheumatoid Arthritis (RA)?

9:00AM-11:00AM: Abstract Number: 1378

Low HDL Level As a Clinical Marker of Disease Activity in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1359

M-DAS28, M-SDAI and M-CDAI Performance in a Cohort of RA Patients with and without Concomitant Fibromyalgia

9:00AM-11:00AM: Abstract Number: 1351

Minimal Clinically Important Improvement (MCII) of RAPID3 (ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3), an INDEX of ONLY Patient Self-Report Scores in Rheumatoid Arthritis (RA): Similar Performance to DAS28 and CDAI

9:00AM-11:00AM: Abstract Number: 1393

Patient Characteristics, Treatment Strategy or Investigator Effect: An Analysis of Factors Driving Variation in Outcomes in Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1395

Patient Reported Outcomes in Rheumatoid Arthritis: Best Domain, Best Interface

9:00AM-11:00AM: Abstract Number: 1384

Physician Global Assessments for Disease Activity in Rheumatoid Arthritis Are All over the Map!

9:00AM-11:00AM: Abstract Number: 1358

Relationship between Serum Protein Pattern and High Disease Activity in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1346

Selective Effect of Rituximab on IgG4 Anti-CCP Autoantibodies in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1380

Serum Galectin-3 in Rheumatoid Arthritis Compared with Healthy Controls and Subjects with Prediabetes before and after High-Intensity Interval Training

9:00AM-11:00AM: Abstract Number: 1389

Serum Progranulin Antibodies (PGRN-abs) in Rheumatoid Arthritis Patients Being Negative for RF-IgM and ACCP-IgG

9:00AM-11:00AM: Abstract Number: 1381

Skeletal Muscle Cytokine and Myostatin Responses to High-Intensity Interval Training in Rheumatoid Arthritis Contrasted with Prediabetes Mellitus

9:00AM-11:00AM: Abstract Number: 1368

Small RNA Sequencing Identifies Plasma microRNA Panel for Rheumatoid Arthritis Diagnosis

9:00AM-11:00AM: Abstract Number: 1348

Swollen Joint Count, but Not Inflammatory Cytokines, Differs By Frequency of Fish Consumption in a Cross-Sectional Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 1345

Tender Joints Have Low Associations with Patient’s Evaluation of Joint Pain and Ultrasound Findings Explored at Joint Level in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1386

Tenosynovitis in the Forefoot at Disease Presentation Is Specific for RA: Results from a Cross-Sectional MRI Study in Early Arthritis

9:00AM-11:00AM: Abstract Number: 1341

The Impact of Anti-Cyclic Citrullinated Peptide Seropositivity on Erosion Prevalence Among Patients with RA of Varying Disease Duration

9:00AM-11:00AM: Abstract Number: 1352

The Relevance of Elevated CRP As an Inclusion Criterion in Clinical Trials in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1377

The Serum Levels of Semaphorin 4D Are Associated with Disease Activity As Well As Radiographic Progression in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1349

Treat to Target: What’s the Target?

9:00AM-11:00AM: Abstract Number: 1347

Ultrasonography and Synovial Histology in the RA Patients in Remission

9:00AM-11:00AM: Abstract Number: 1350

Ultrasound Detected Tenosynovitis in Rheumatoid Arthritis Patients in Clinical Remission

9:00AM-11:00AM: Abstract Number: 1373

Ultrasound of Subtalar Joint Synovitis in Patients with Rheumatoid Arthritis: Results of an Omeract Reliability Exercise Using Consensual Definitions

9:00AM-11:00AM: Abstract Number: 1391

Ultrasound Response to Tocilizumab in Surgically Replaced Joints and Surgically Operated Joint Areas of Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1360

Validation of the Health Assessment Questionnaire-Upper Extremity (HAQUP) in Patients with Rheumatoid Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].